COVID-19

HR+

Questions discussed in this category

In the setting of COVID-19, would you perform a SLNB for a patient incidentally found to have microinvasive ER+ ILC in contralateral prophylactic mastectomy following neoadjuvant chemotherapy for a locally advanced triple positive breast cancer?

2 Answers available

Would you choose neoadjuvant endocrine therapy for a low grade, node negative, ER/PR positive, breast cancer given delays in definitive surgery due to the COVID-19 pandemic?

Would your choice vary based on the patient's gender?

1 Answer available

How would you approach adjuvant therapy in a patient with HR+ breast cancer with a high RS (>25) given the current COVID-19 pandemic?

Would you consider delaying chemotherapy and proceeding only with endocrine for now?

2 Answers available

Papers discussed in this category

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006-08-10

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.

The New England journal of medicine, 2018-07-12

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.

JAMA Oncol, 2019 Sep 30

Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial.

JAMA,

Coronavirus Disease 2019 (COVID-19) in Italy.

N Engl J Med, 2020 Mar 27

Epidemiology of Covid-19 in a Long-Term Care Facility in King County, Washington.

J. Clin. Oncol., 2019 Jul 24

Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial.

Related Topics in COVID-19